Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2024-01-01 DOI:10.3233/TUB-230001

Anika Mang, Wei Zou, Vinzent Rolny, Martin Reck, Daniel Cigoianu, Katja Schulze, Stefan Holdenrieder, Mark A Socinski, David S Shames, Birgit Wehnl, Namrata S Patil

{"title":"Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.","authors":"Anika Mang, Wei Zou, Vinzent Rolny, Martin Reck, Daniel Cigoianu, Katja Schulze, Stefan Holdenrieder, Mark A Socinski, David S Shames, Birgit Wehnl, Namrata S Patil","doi":"10.3233/TUB-230001","DOIUrl":null,"url":null,"abstract":"Background: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments.Objective: To evaluate the potential of tumor biomarkers to inform on survival outcomes in NSCLC SD patients.Methods: This post hoc analysis included 480 patients from the IMpower150 study with metastatic NSCLC, treated with chemotherapy, atezolizumab and bevacizumab combinations, who had SD at first CT scan (post-treatment initiation). Patients were stratified into high- and low-risk groups (overall survival [OS] and progression-free survival [PFS] outcomes) based on serum tumor biomarker levels.Results: The CYFRA 21-1 and CA 125 biomarker combination predicted OS and PFS in patients with SD. Risk of death was ~4-fold higher for the biomarker-stratified high-risk versus low-risk SD patients (hazard ratio [HR] 3.80; 95% confidence interval [CI] 3.02-4.78; p < 0.0001). OS in patients with the low- and high-risk SD was comparable to that in patients with the CT-defined partial response (PR; HR 1.10; 95% CI 0.898-1.34) and progressive disease (PD) (HR 1.05; 95% CI 0.621-1.77), respectively. The findings were similar with PFS, and consistent across treatment arms.Conclusions: Biomarker testing shows potential for providing prognostic information to help direct treatment in NSCLC patients with SD. Prospective clinical studies are warranted.ClinicalTrials.gov: NCT02366143.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":"S177-S190"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-230001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments.

Objective: To evaluate the potential of tumor biomarkers to inform on survival outcomes in NSCLC SD patients.

Methods: This post hoc analysis included 480 patients from the IMpower150 study with metastatic NSCLC, treated with chemotherapy, atezolizumab and bevacizumab combinations, who had SD at first CT scan (post-treatment initiation). Patients were stratified into high- and low-risk groups (overall survival [OS] and progression-free survival [PFS] outcomes) based on serum tumor biomarker levels.

Results: The CYFRA 21-1 and CA 125 biomarker combination predicted OS and PFS in patients with SD. Risk of death was ~4-fold higher for the biomarker-stratified high-risk versus low-risk SD patients (hazard ratio [HR] 3.80; 95% confidence interval [CI] 3.02-4.78; p < 0.0001). OS in patients with the low- and high-risk SD was comparable to that in patients with the CT-defined partial response (PR; HR 1.10; 95% CI 0.898-1.34) and progressive disease (PD) (HR 1.05; 95% CI 0.621-1.77), respectively. The findings were similar with PFS, and consistent across treatment arms.

Conclusions: Biomarker testing shows potential for providing prognostic information to help direct treatment in NSCLC patients with SD. Prospective clinical studies are warranted.ClinicalTrials.gov: NCT02366143.

查看原文本刊更多论文

联合使用 CYFRA 21-1 和 CA 125 预测转移性 NSCLC 患者的生存率和 IMpower150 中疾病的稳定性。

背景：非小细胞肺癌（NSCLC）和病情稳定（SD）患者的临床需求尚未得到满足非小细胞肺癌（NSCLC）和疾病稳定期（SD）患者对指导早期治疗的临床需求尚未得到满足：目的：评估肿瘤生物标记物对NSCLC SD患者生存结果的潜在影响：这项事后分析纳入了IMpower150研究中的480例转移性NSCLC患者，这些患者接受了化疗、阿替佐珠单抗和贝伐珠单抗联合治疗，并在首次CT扫描（治疗开始后）时出现SD。根据血清肿瘤生物标志物水平将患者分为高风险组和低风险组（总生存期[OS]和无进展生存期[PFS]结果）：结果：CYFRA 21-1和CA 125生物标志物组合可预测SD患者的OS和PFS。经生物标志物分层的高危 SD 患者与低危 SD 患者相比，死亡风险高出约 4 倍（危险比 [HR] 3.80；95% 置信区间 [CI] 3.02-4.78；P 结论：生物标志物检测显示了治疗 SD 的潜力：生物标志物检测显示出提供预后信息的潜力，有助于指导NSCLC SD患者的治疗。有必要进行前瞻性临床研究：NCT02366143。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).